<DOC>
	<DOCNO>NCT00046748</DOCNO>
	<brief_summary>The purpose study determine effect omalizumab , compare placebo , clinically significant asthma exacerbation rate adolescent adult asthma .</brief_summary>
	<brief_title>Efficacy Safety Omalizumab Patients With Severe Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>diagnosis allergic asthma &gt; 1 year duration , addition standard American Thoracic Society ( ATS ) meet follow criterion : positive prick skin test ( diameter wheal &gt; 3 mm ) least one perennial allergen ( e.g . dust mite , animal dander , cockroach ) , within past 5 year Visit 1 , patient expose regular basis ( day ) duration study . A RAST test may perform patient borderline skin prick test result . total serum IgE level 30 700 IU/ml . demonstrate 12 % increase FEV1 baseline value within 30 minute take 4 puff salbutamol ( albuterol ) nebulized salbutamol 5mg ( equivalent alternative B2 agonist ) document within past year , screening , runin period baseline prior randomization . FEV1 4080 % predict normal value patient ( demonstrable least 6 hour short act B2 agonist use 12 hour long act B2 agonist use ) baseline . either experience least two independent asthma exacerbation require unscheduled clinical intervention systemic corticosteroid past year . : admitted hospital ( include intensive care unit ) receive emergency room ( include urgent care center ) treatment past 12 month asthma exacerbation , accordance GINA guideline meet follow criterion severe exacerbation : 1 . PEF FEV1 &lt; 60 % predicted/personal best , patient breathless provide PEF . 2 . No improvement initial treatment therefore require repeat treatment inhale B2 agonist ( high dose , spacer nebulized ) . 3 . Requiring treatment systemic corticosteroid receive high dose inhale corticosteroid ( least 1000ug beclomethasone dipropionate equivalent ) regular inhale long act B2 agonist least 3 month prior screen prior least two independent asthma exacerbation require unscheduled clinical intervention systemic corticosteroid past year severe asthma exacerbation require hospitalization/ER visit . receive ICS dosage &gt; 1000ug beclomethasone dipropionate equivalent regular inhale long act B2 agonist last 4 week runin period randomization ( maintain throughout study ) . whose asthma medication remain unchanged final 4 week runin period ( maintain throughout study ) . evidence poor asthma symptom control screen ( base patient history ) 4 week immediately prior baseline .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>